Synthesis and anti-prion aggregation activity of acylthiosemicarbazide analogues

References

• Prusiner SB. Prions. Proc Natl Acad Sci USA. 1998;95(23):13363–13383.
   PubMed Web of Science ®Google Scholar
• Ryou C. Prions and prion diseases: fundamentals and mechanistic details. J Microbiol Biotechnol. 2007;17(7):1059–1070.
   PubMed Web of Science ®Google Scholar
• Prusiner SB. The prion diseases. Brain Pathol. 1998;8(3):499–513.
   PubMed Web of Science ®Google Scholar
• Ritchie DL, Ironside JW. Neuropathology of human prion diseases. Prog Mol Biol Transl Sci. 2017;150:319–339.
   PubMed Web of Science ®Google Scholar
• Lakkaraju AKK, Frontzek K, Lemes E, Herrmann U, Losa M, Marpakwar R, Aguzzi A. Loss of PIKfyve drives the spongiform degeneration in prion diseases. EMBO Mol Med. 2021;13(9):e14714.
   PubMed Web of Science ®Google Scholar
• Frontzek K, Bardelli M, Senatore A, Henzi A, Reimann RR, Bedir S, Marino M, Hussain R, Jurt S, Meisl G, et al. A conformational switch controlling the toxicity of the prion protein. Nat Struct Mol Biol. 2022;29(8):831–840.
   PubMed Web of Science ®Google Scholar
• Tuite MF, Serio TR. The prion hypothesis: from biological anomaly to basic regulatory mechanism. Nat Rev Mol Cell Biol. 2010;11(12):823–833.
   PubMed Web of Science ®Google Scholar
• Ryou C, Mays CE. Prion propagation in vitro: are we there yet? Int J Med Sci. 2008;5(6):347–353.
   PubMedGoogle Scholar
• Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216(4542):136–144.
   PubMed Web of Science ®Google Scholar
• Kraus A, Hoyt F, Schwartz CL, Hansen B, Artikis E, Hughson AG, Raymond GJ, Race B, Baron GS, Caughey B. High-resolution structure and strain comparison of infectious mammalian prions. Mol Cell. 2021;81(21):4540–4551.e6.
   PubMed Web of Science ®Google Scholar
• Hoyt F, Standke HG, Artikis E, Schwartz CL, Hansen B, Li K, Hughson AG, Manca M, Thomas OR, Raymond GJ, et al. Cryo-EM structure of anchorless RML prion reveals variations in shared motifs between distinct strains. Nat Commun. 2022;13(1):4005.
   PubMed Web of Science ®Google Scholar
• Safar J, Prusiner SB. Molecular studies of prion diseases. Prog Brain Res. 1998;117:421–434.
   PubMed Web of Science ®Google Scholar
• Supattapone S, Nguyen HO, Cohen FE, Prusiner SB, Scott MR. Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci USA. 1999;96(25):14529–14534.
   PubMed Web of Science ®Google Scholar
• Solassol J, Crozet C, Perrier V, Leclaire J, Beranger F, Caminade AM, Meunier B, Dormont D, Majoral JP, Lehmann S. Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. J Gen Virol. 2004;85(Pt 6):1791–1799.
   PubMedGoogle Scholar
• Haïk S, Marcon G, Mallet A, Tettamanti M, Welaratne A, Giaccone G, Azimi S, Pietrini V, Fabreguettes J-R, Imperiale D, et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(2):150–158.
   PubMed Web of Science ®Google Scholar
• Lim YB, Mays CE, Kim Y, Titlow WB, Ryou C. The inhibition of prions through blocking prion conversion by permanently charged branched polyamines of low cytotoxicity. Biomaterials. 2010;31(8):2025–2033.
   PubMed Web of Science ®Google Scholar
• Ryou C, Legname G, Peretz D, Craig JC, Baldwin MA, Prusiner SB. Differential inhibition of prion propagation by enantiomers of quinacrine. Lab Invest. 2003;83(6):837–843.
   PubMed Web of Science ®Google Scholar
• Murakami-Kubo I, Doh-Ura K, Ishikawa K, Kawatake S, Sasaki K, Kira JI, Ohta S, Iwaki T. Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies. J Virol. 2004;78(3):1281–1288.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Kaku-Ushiki Y, Iwamaru Y, Muramoto T, Kitamoto T, Yokoyama T, Mohri S, Tagawa Y. A novel anti-prion protein monoclonal antibody and its single-chain fragment variable derivative with ability to inhibit abnormal prion protein accumulation in cultured cells. Microbiol Immunol. 2010;54(2):112–121.
   PubMed Web of Science ®Google Scholar
• Kim DH, Ren C, Ryou C, Li J. Direct interaction of DNMT inhibitors to PrP(C) suppresses pathogenic process of prion. Acta Pharm Sin B. 2019;9(5):952–959.
   PubMed Web of Science ®Google Scholar
• Kuwata K, Nishida N, Matsumoto T, Kamatari YO, Hosokawa-Muto J, Kodama K, Nakamura HK, Kimura K, Kawasaki M, Takakura Y, et al. Hot spots in prion protein for pathogenic conversion. Proc Natl Acad Sci USA. 2007;104(29):11921–11926.
   PubMed Web of Science ®Google Scholar
• Kimura T, Hosokawa-Muto J, Kamatari YO, Kuwata K. Synthesis of GN8 derivatives and evaluation of their antiprion activity in TSE-infected cells. Bioorg Med Chem Lett. 2011;21(5):1502–1507.
   PubMed Web of Science ®Google Scholar
• Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA. 2001;98(17):9836–9841.
   PubMed Web of Science ®Google Scholar
• Ishibashi D, Nakagaki T, Ishikawa T, Atarashi R, Watanabe K, Cruz FA, Hamada T, Nishida N. Structure-based drug discovery for prion disease using a novel binding simulation. eBiomedicine. 2016;9:238–249.
   PubMed Web of Science ®Google Scholar
• Li JJ, Ryou C, Kim DH. Effects of SGI-1027 on formation and elimination of PrPSc in prion-infected cells. Mol Biol. 2020;54(3):412–415.
   Web of Science ®Google Scholar
• Telling GC, Scott M, Mastrianni J, Gabizon R, Torchia M, Cohen FE, DeArmond SJ, Prusiner SB. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell. 1995;83(1):79–90.
   PubMed Web of Science ®Google Scholar
• Kaneko K, Zulianello L, Scott M, Cooper CM, Wallace AC, James TL, Cohen FE, Prusiner SB. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc Natl Acad Sci USA. 1997;94(19):10069–10074.
   PubMed Web of Science ®Google Scholar
• Mays CE, Ryou C. Plasminogen stimulates propagation of protease-resistant prion protein in vitro. Faseb J. 2010;24(12):5102–5112.
   PubMed Web of Science ®Google Scholar
• Baldeschi AC, Zattoni M, Vanni S, Nikolic L, Ferracin C, La Sala G, Summa M, Bertorelli R, Bertozzi SM, Giachin G, et al. Innovative non-PrP-targeted drug strategy designed to enhance prion clearance. J Med Chem. 2022;65(13):8998–9010.
   PubMed Web of Science ®Google Scholar
• Ali T, Hannaoui S, Nemani S, Tahir W, Zemlyankina I, Cherry P, Shim SY, Sim V, Schaetzl HM, Gilch S. Oral administration of repurposed drug targeting CYP46A1 increases survival times of prion infected mice. Acta Neuropathol Commun. 2021;9(1):58.
   PubMed Web of Science ®Google Scholar
• Ryou C, Titlow WB, Mays CE, Bae Y, Kim S. The suppression of prion propagation using poly-L-lysine by targeting plasminogen that stimulates prion protein conversion. Biomaterials. 2011;32(11):3141–3149.
   PubMed Web of Science ®Google Scholar
• Barreca ML, Iraci N, Biggi S, Cecchetti V, Biasini E. Pharmacological agents targeting the cellular prion protein. Pathogens. 2018;7(1):27.
   PubMed Web of Science ®Google Scholar
• Trevitt CR, Collinge J. A systemic review of prion therapeutics in experimental models. Brain. 2006;129(9):2241–2265.
   PubMedGoogle Scholar
• Choi H, Yun W, Lee JH, Jang S, Park SW, Kim DH, Seon KP, Hyun JM, Jeong K, Ku JM, et al. Synthesis and anti-endoplasmic reticulum stress activity of N-substituted-2-arylcarbonylhydrazinecarbothioamides. Med Chem Res. 2019;28(12):2142–2152.
   Web of Science ®Google Scholar
• Doyle KM, Kennedy D, Gorman AM, Gupta S, Healy SJ, Samali A. Unfolded proteins and endoplasmic reticulum stress in neurodegenerative disorders. J Cell Mol Med. 2011;15(10):2025–2039.
   PubMed Web of Science ®Google Scholar
• Yoshida H. ER stress and diseases. Febs J. 2007;274(3):630–658.
   PubMed Web of Science ®Google Scholar
• Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta. 2013;1833(12):3460–3470.
   PubMed Web of Science ®Google Scholar
• Jeon JH, Im S, Kim HS, Lee D, Jeong K, Ku JM, Nam TG. Chemical chaperones to inhibit endoplasmic reticulum stress: implications in diseases. DDDT. 2022;16:4385–4397.
   PubMed Web of Science ®Google Scholar
• Kim SG, Lee HM, Ryou C. Parameters that affect macromolecular self-assembly of prion protein. Protein J. 2014;33(3):243–252.
   PubMed Web of Science ®Google Scholar
• Bocharova OV, Breydo L, Parfenov AS, Salnikov VV, Baskakov IV. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc). J Mol Biol. 2005;346(2):645–659.
   PubMed Web of Science ®Google Scholar
• Hwang HG, Kim DH, Lee J, Mo Y, Lee SH, Lee Y, Hyeon JW, Lee SM, Cheon YP, Choi EK, et al. High-level production of high-purity human and murine recombinant prion proteins functionally compatible to in vitro seeding assay. J Microbiol Biotechnol. 2018;28(10):1749–1759.
   PubMed Web of Science ®Google Scholar
• Dean DN, Das PK, Rana P, Burg F, Levites Y, Morgan SE, Ghosh P, Rangachari V. Strain-specific fibril propagation by an Abeta dodecamer. Sci Rep. 2017;7(1):40787.
   PubMedGoogle Scholar
• Halfmann R, Lindquist S. Screening for amyloid aggregation by semi-denaturing detergent-agarose gel electrophoresis. J Vis Exp. 2008;17:838.
   Google Scholar
• Wilham JM, Orru CD, Bessen RA, Atarashi R, Sano K, Race B, Meade-White KD, Taubner LM, Timmes A, Caughey B. Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. PLoS Pathog. 2010;6(12):e1001217.
   PubMed Web of Science ®Google Scholar
• Atarashi R, Wilham JM, Christensen L, Hughson AG, Moore RA, Johnson LM, Onwubiko HA, Priola SA, Caughey B. Simplified ultrasensitive prion detection by recombinant PrP conversion with shaking. Nat Methods. 2008;5(3):211–212.
   PubMed Web of Science ®Google Scholar
• Waqas M, Lee HM, Kim J, Telling G, Kim JK, Kim DH, Ryou C. Effect of poly-L-arginine in inhibiting scrapie prion protein of cultured cells. Mol Cell Biochem. 2017;428(1–2):57–66.
   PubMed Web of Science ®Google Scholar
• Lee S, Lee H, Kim J, Kim JH, Gao EM, Lee Y, Yoo M, Trinh THT, Kim J, Kim CY, et al. The effect of Curcuma phaeocaulis Valeton (Zingiberaceae) extract on prion propagation in cell-based and animal models. IJMS. 2022;24(1):182.
   Google Scholar
• Biancalana M, Koide S. Molecular mechanism of thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta. 2010;1804(7):1405–1412.
   PubMed Web of Science ®Google Scholar
• Kang HE, Mo Y, Abd Rahim R, Lee HM, Ryou C. Prion diagnosis: application of real-time quaking-induced conversion. Biomed Res Int. 2017;2017:1–8.
   Web of Science ®Google Scholar
• Cheng K, Sloan A, Waitt B, Vendramelli R, Godal D, Simon SLR, O'Neil J, Carpenter M, Jackson D, Eastlake J, et al. Altered rPrP substrate structures and their influence on real-time quaking induced conversion reactions. Protein Expr Purif. 2018;143:20–27.
   PubMed Web of Science ®Google Scholar
• Abskharon R, Dang J, Elfarash A, Wang Z, Shen P, Zou LS, Hassan S, Wang F, Fujioka H, Steyaert J, et al. Soluble polymorphic bank vole prion proteins induced by co-expression of quiescin sulfhydryl oxidase in E. coli and their aggregation behaviors. Microb Cell Fact. 2017;16(1):170.
   PubMedGoogle Scholar
• Yen CF, Harischandra DS, Kanthasamy A, Sivasanka S. Copper-induced structural conversion templates prion protein oligomerization and neurotoxicity. Sci Adv. 2016;2(7):e1600014.
   PubMed Web of Science ®Google Scholar
• Kim YE, Kim DH, Choi A, Jang S, Jeong K, Kim YM, Nam TG. Bi-aryl analogues of salicylic acids: design, synthesis and SAR study to ameliorate endoplasmic reticulum stress. DDDT. 2021;15:3593–3604.
   PubMed Web of Science ®Google Scholar
• Simoneau S, Rezaei H, Salès N, Kaiser-Schulz G, Lefebvre-Roque M, Vidal C, Fournier JG, Comte J, Wopfner F, Grosclaude J, et al. In vitro and in vivo neurotoxicity of prion protein oligomers. PLoS Pathog. 2007;3(8):e125.
   PubMed Web of Science ®Google Scholar